199 related articles for article (PubMed ID: 18063500)
1. Effect of glyburide-metformin combination tablet in patients with type 2 diabetes.
Chien HH; Chang CT; Chu NF; Hsieh SH; Huang YY; Lee IT; Lee WJ; Tang YJ; Sheu WH
J Chin Med Assoc; 2007 Nov; 70(11):473-80. PubMed ID: 18063500
[TBL] [Abstract][Full Text] [Related]
2. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.
Garber AJ; Bruce S; Fiedorek FT
Clin Ther; 2002 Sep; 24(9):1401-13. PubMed ID: 12380632
[TBL] [Abstract][Full Text] [Related]
3. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.
Lewin A; Lipetz R; Wu J; Schwartz S
Clin Ther; 2007 May; 29(5):844-855. PubMed ID: 17697903
[TBL] [Abstract][Full Text] [Related]
4. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
Dailey GE; Mohideen P; Fiedorek FT
Clin Ther; 2002 Sep; 24(9):1426-38. PubMed ID: 12380634
[TBL] [Abstract][Full Text] [Related]
5. Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy.
Blonde L; Rosenstock J; Mooradian AD; Piper BA; Henry D
Diabetes Obes Metab; 2002 Nov; 4(6):368-75. PubMed ID: 12406033
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes.
Garber AJ; Larsen J; Schneider SH; Piper BA; Henry D;
Diabetes Obes Metab; 2002 May; 4(3):201-8. PubMed ID: 12047399
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes.
Garber AJ; Donovan DS; Dandona P; Bruce S; Park JS
J Clin Endocrinol Metab; 2003 Aug; 88(8):3598-604. PubMed ID: 12915642
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
DeFronzo RA; Goodman AM
N Engl J Med; 1995 Aug; 333(9):541-9. PubMed ID: 7623902
[TBL] [Abstract][Full Text] [Related]
9. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Garber A; Klein E; Bruce S; Sankoh S; Mohideen P
Diabetes Obes Metab; 2006 Mar; 8(2):156-63. PubMed ID: 16448519
[TBL] [Abstract][Full Text] [Related]
10. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.
Dailey GE; Noor MA; Park JS; Bruce S; Fiedorek FT
Am J Med; 2004 Feb; 116(4):223-9. PubMed ID: 14969649
[TBL] [Abstract][Full Text] [Related]
11. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin.
Marre M; Howlett H; Lehert P; Allavoine T
Diabet Med; 2002 Aug; 19(8):673-80. PubMed ID: 12147149
[TBL] [Abstract][Full Text] [Related]
12. Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance) in type 2 diabetes.
Garber A; Marre M; Blonde L; Allavoine T; Howlett H; Lehert P; Cornes M
Diabetes Obes Metab; 2003 May; 5(3):171-9. PubMed ID: 12681024
[TBL] [Abstract][Full Text] [Related]
13. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
Goldstein BJ; Pans M; Rubin CJ
Clin Ther; 2003 Mar; 25(3):890-903. PubMed ID: 12852706
[TBL] [Abstract][Full Text] [Related]
14. The combination metformin/glyburide exerts its hypoglycemic effect mainly by increasing insulin secretion: a controlled, randomized, double-blind, crossover study.
Gulias-Herrero A; Aguilar-Salinas CA; Gómez-Pérez FJ; Rull JA
Diabetes Nutr Metab; 2003; 16(5-6):268-76. PubMed ID: 15000437
[TBL] [Abstract][Full Text] [Related]
15. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.
Erle G; Lovise S; Stocchiero C; Lora L; Coppini A; Marchetti P; Merante D
Acta Diabetol; 1999 Jun; 36(1-2):61-5. PubMed ID: 10436254
[TBL] [Abstract][Full Text] [Related]
16. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.
Wolffenbuttel BH; Landgraf R
Diabetes Care; 1999 Mar; 22(3):463-7. PubMed ID: 10097930
[TBL] [Abstract][Full Text] [Related]
17. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Kahn SE; Haffner SM; Heise MA; Herman WH; Holman RR; Jones NP; Kravitz BG; Lachin JM; O'Neill MC; Zinman B; Viberti G;
N Engl J Med; 2006 Dec; 355(23):2427-43. PubMed ID: 17145742
[TBL] [Abstract][Full Text] [Related]
18. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin.
Gerich J; Raskin P; Jean-Louis L; Purkayastha D; Baron MA
Diabetes Care; 2005 Sep; 28(9):2093-9. PubMed ID: 16123472
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
Pratley RE; Kipnes MS; Fleck PR; Wilson C; Mekki Q;
Diabetes Obes Metab; 2009 Feb; 11(2):167-76. PubMed ID: 19125778
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
Karyekar C; Donovan M; Allen E; Fleming D; Ravichandran S; Chen R
Postgrad Med; 2011 Jul; 123(4):63-70. PubMed ID: 21680990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
